Nothing CHTP related. I would consider this a "buy the weakness" moment - good day to add more if you were considering it before. http://blogs.marketwatch.com/health-exchange/2014/03/24/biotech-has-a-second-straight-sell-off-sector-mutual-funds-take-it-on-chin/ 'nough said.